Last reviewed · How we verify
N-Acetyl-L-Leucine — Competitive Intelligence Brief
phase 3
Amino acid metabolic enhancer
Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
N-Acetyl-L-Leucine (N-Acetyl-L-Leucine) — IntraBio Inc. N-Acetyl-L-Leucine enhances mitochondrial energy metabolism and reduces neuroinflammation to improve vestibular and cerebellar function.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| N-Acetyl-L-Leucine TARGET | N-Acetyl-L-Leucine | IntraBio Inc | phase 3 | Amino acid metabolic enhancer |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Amino acid metabolic enhancer class)
- IntraBio Inc · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- N-Acetyl-L-Leucine CI watch — RSS
- N-Acetyl-L-Leucine CI watch — Atom
- N-Acetyl-L-Leucine CI watch — JSON
- N-Acetyl-L-Leucine alone — RSS
- Whole Amino acid metabolic enhancer class — RSS
Cite this brief
Drug Landscape (2026). N-Acetyl-L-Leucine — Competitive Intelligence Brief. https://druglandscape.com/ci/n-acetyl-l-leucine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab